Akoya BioSciences Inc.

19.53-0.4100-2.06%Vol 117.63K1Y Perf -24.18%
Jun 14th, 2021 16:00 DELAYED
BID19.52 ASK19.69
Open20.16 Previous Close19.94
Pre-Market- After-Market-
 - -  - -%
Target Price
25.50 
Analyst Rating
— — 0.00
Potential %
30.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+ —    44.63
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap724.78M 
Earnings Rating
Price Range Ratio 52W %
22.26 
Earnings Date
-

Today's Price Range

19.4220.50

52W Range

16.8328.96

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Neutral
Performance
1 Week
-2.79%
1 Month
-4.26%
3 Months
-
6 Months
-
1 Year
-24.18%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AKYA19.53-0.4100-2.06
AAPL130.483.13002.46
GOOG2 527.0413.11000.52
MSFT259.892.00000.78
XOM62.07-0.1000-0.16
WFC45.15-0.5300-1.16
JNJ165.370.41000.25
FB336.775.51001.66
GE13.47-0.2200-1.61
JPM157.57-2.7200-1.70
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.15-2.85-1 800.00
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume117.63K
Shares Outstanding37.11M
Trades Count3.19K
Dollar Volume0
Avg. Volume138.07K
Avg. Weekly Volume62.17K
Avg. Monthly Volume74.63K
Avg. Quarterly Volume138.07K

Akoya BioSciences Inc. (NASDAQ: AKYA) stock closed at 19.53 per share at the end of the most recent trading day (a -2.06% change compared to the prior day closing price) with a volume of 117.63K shares and market capitalization of 724.78M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 169 people. Akoya BioSciences Inc. CEO is Brian McKelligon.

The one-year performance of Akoya BioSciences Inc. stock is -24.18%, while year-to-date (YTD) performance is %. AKYA stock has a five-year performance of %. Its 52-week range is between 16.83 and 28.96, which gives AKYA stock a 52-week price range ratio of 22.26%

Akoya BioSciences Inc. currently has a PE ratio of -22.10, a price-to-book (PB) ratio of 41.23, a price-to-sale (PS) ratio of 16.61, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.19%, a ROC of -% and a ROE of 45.22%. The company’s profit margin is -51.90%, its EBITDA margin is -36.30%, and its revenue ttm is $43.63 Million , which makes it $1.18 revenue per share.

Of the last four earnings reports from Akoya BioSciences Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Akoya BioSciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Akoya BioSciences Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Akoya BioSciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Akoya BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Akoya BioSciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.79, ATR14 : 1.20, CCI20 : -102.05, Chaikin Money Flow : -0.37, MACD : -0.34, Money Flow Index : 31.29, ROC : -6.73, RSI : 37.14, STOCH (14,3) : 4.03, STOCH RSI : 0.00, UO : 34.69, Williams %R : -95.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Akoya BioSciences Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Akoya BioSciences Inc.

Akoya Biosciences Inc is an an innovative life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. It offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications.

CEO: Brian McKelligon

Telephone: +1 855 896-8401

Address: 100 Campus Drive, 6th Floor, Marlborough 01752, MA, US

Number of employees: 169

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

67%33%

Bearish Bullish

67%33%

News

Stocktwits